RGEN - Repligen EPS beats by $0.25 beats on revenue; increases FY 2021 guidance

Repligen (RGEN): Q1 Non-GAAP EPS of $0.68; GAAP EPS of $0.52 beats by $0.25.Revenue of $142.8M (+87.7% Y/Y) beats by $25.78M.Organic Revenue growth of 69%.FISCAL YEAR 2021 GUIDANCE:  Total revenue is expected to be in the range of $565-$590 million ($513.38M consensus) (previous $500-$525M) , reflecting overall revenue growth of 54%-61% and 52%-59% at constant currency and organic growth of 42%-49%, an increase from our previous guidance of 26%-33%.Revenue contribution from COVID-related programs are expected to be in the range of $140-$160 million, an increase from our previous guidance of $90-$100 million. This represents incremental COVID-related revenue of $94-$114 million compared to 2020, representing 26-31 points of overall revenue growth.Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis.Income from operations is expected to be in the range of $127-$133 million on a GAAP basis, an increase from our previous guidance of $103-$109 million. Adjusted (non-GAAP) income from operations is expected to be

For further details see:

Repligen EPS beats by $0.25, beats on revenue; increases FY 2021 guidance